63 results on '"Moriggl, Richard"'
Search Results
2. Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metalloproteinase Induction.
- Author
-
Tsareva, Svetlana A., Moriggl, Richard, Corvinus, Florian M., Wiederanders, Bernd, Schüt, Alexander, Kovacic, Boris, and Friedrich, Karlheinz
- Subjects
- *
COLON cancer , *CANCER cells , *CELL lines , *MESSENGER RNA , *METALLOPROTEINASES , *ENZYMES , *TUMORS , *CANCER invasiveness - Abstract
Signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in colorectal carcinomas (CRCs). Here, we define the relationship between STAT3 function and the malignant properties of colon carcinoma cells. Elevated activation of STAT3 enhances invasive growth of the CRC cell lines. To address mechanisms through which STAT3 influences invasiveness, the protease mRNA expression pattern of CRC biopsies was analyzed and correlated with the STAT3 activity status. These studies revealed a striking coincidence of STAT3 activation and strong expression of matrix metalloproteinases MMP-1, -3, -7, and -9. Immunohistological examination of CRC tumor specimens showed a clear colocalization of MMP-1 and activated STAT3. Experimentally induced STAT3 activity in CRC cell lines enhanced both the level of MMP-1 mRNA and secreted MMP-1 enzymatic activity. A direct connection of STAT3 activity and transcription from the MMP-1 promoter was shown by reporter gene experiments. Moreover, high-affinity binding of STAT3 to STAT recognition elements in both the MMP-1 and MMP-3 promoter was demonstrated. Xenograft tumors arising from implantation of CRC cells into nude mice showed simultaneous appearance and colocalization of p-Y-STAT3 and MMP-1 expression. Our results link aberrant activity of STAT3 in CRC to malignant tumor progression through upregulated expression of MMPs. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
3. Stat5 tetramer formation is associated with leukemogenesis
- Author
-
Moriggl, Richard, Sexl, Veronika, Kenner, Lukas, Duntsch, Christopher, Stangl, Katharina, Gingras, Sebastien, Hoffmeyer, Angelika, Bauer, Anton, Piekorz, Roland, Wang, Demin, Bunting, Kevin D., Wagner, Erwin F., Sonneck, Karoline, Valent, Peter, Ihle, James N., and Beug, Hartmut
- Subjects
- *
TETRAMERS (Oligomers) , *LEUKEMIA , *CANCER , *BONE marrow , *IMMUNE system - Abstract
Activation of Stat5 is frequently found in leukemias. To study the mechanism and role of Stat5 activation, we introduced a constitutively activated Stat5a mutant, cS5F, into murine bone marrow (BM) cells. BM transplantation with cS5F-transfected cells caused development of multilineage leukemias in lethally irradiated wild-type or nonirradiated Rag2−/− mice. The leukemic cells showed strongly enhanced levels of cS5F tetramers but unchanged cS5F dimer levels in a DNA binding assay. Moreover, Stat5a mutants engineered to form only dimers, but not tetramers, failed to induce leukemias. In addition, Stat5 tetramers were found to accumulate in excess compared to dimers in various human leukemias. These data suggest that Stat5 tetramers are associated with leukemogenesis. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
4. A small amphipathic a-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5.
- Author
-
Wang, Demin, Moriggl, Richard, Stravopodis, Dimitrios, Carpino, Nick, Marine, Jean-Christophe, Teglund, Stephan, Feng, Jian, and Ihle, James N.
- Subjects
- *
CYTOKINES , *PHOSPHORYLATION , *CHEMICAL reactions , *TRANSCRIPTION factors , *BIOCHEMISTRY , *PROTEIN-tyrosine phosphatase - Abstract
Cytokines induce the tyrosine phosphorylation and associated activation of signal transducers and activators of transcription (Stat). The mechanisms by which this response is terminated are largely unknown. Among a variety of inhibitors examined, the proteasome inhibitors MG132 and lactacystin affected Stat4, Stats and Stat6 turnover by significantly stabilizing the tyrosine-phosphorylated form. However, these proteasome inhibitors did not affect downregulation of the tyrosine-phosphorylated Stat1, Stat2 and Stat3. With Stats isoforms, we have observed that tyrosine-phosphorylated carboxyl-truncated forms of Stats proteins were considerably more stable than phosphorylated wild-type forms of the protein. Also, the C-terminal region of Stats could confer proteasome-dependent downregulation to Stat1. With a series of C-terminal deletion mutants, we have defined a relatively small, potentially amphipathic α-helical region that is required for the rapid turnover of the phosphorylated Stats proteins. The region is also required for transcriptional activation, suggesting that the functions are linked. The results are consistent with a model in which the transcriptional activation domain of activated Stats is required for its transcriptional activity and downregulation through a proteasome-dependent pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
5. Unveiling myeloid transformation: T‐LGLL with eosinophilia masking myeloid‐associated STAT5B mutation culminating in AML.
- Author
-
Dong, Qianze, Wang, Yang, Xiu, Yan, Wu, Xiaogang, O'Neill, Stacey, Meyerson, Howard, Suske, Tobias, Moriggl, Richard, Hu, Shimin, Wang, Wei, and Zhao, Chen
- Subjects
- *
GAIN-of-function mutations , *EOSINOPHILIA , *ACUTE myeloid leukemia , *GENETIC mutation , *SOMATIC mutation , *PULMONARY eosinophilia , *HYPEREOSINOPHILIC syndrome - Abstract
This article discusses a case study of a 67-year-old woman who initially presented with T-cell large granular lymphocytic leukemia (T-LGLL) with eosinophilia. However, as the disease progressed, it transformed into acute myeloid leukemia (AML) originating from mutated myeloid cells. The study explores the clonal relationships and evolution of different cell populations and highlights the role of the STAT5B mutation in the development of myeloid neoplasms. The research suggests that STAT5B alone can induce myeloid leukemia and that the same mutation in different cell lineages can lead to diverse types of neoplasms. Further research is needed to understand the pathogenesis of STAT5B-mutated neoplasms and develop specific inhibitors. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
6. Activation of STAT6 is not dependent on phosphotyrosine-mediated docking to the interleukin-4 receptor and can be blocked by dominant-negative mutants of both receptor subunits.
- Author
-
Moriggl, Richard, Erhardt, Ingrid, Kammer, Winfried, Berchtold, Susanne, Schnarr, Bernd, Lischke, Antje, Groner, Bernd, and Friedrich, Karlheinz
- Subjects
- *
CELLULAR signal transduction , *TRANSCRIPTION factors , *PHOSPHORYLATION , *INTERLEUKIN-4 - Abstract
Stimulation of susceptible cells by interleukin-4 leads to activation of signal transducer and activator of transcription (STAT6) through tyrosine phosphorylation and dimerisation, thus directing it to the cell nucleus and rendering it a sequence-specific transcription factor. We functionally reconstituted human interleukin-4 receptor complexes with intracellular truncations of either the α or γ subunits and demonstrate the requirement for elements from both receptor chains for STAT6 activation induced by interleukin-4. By assaying the signalling properties of human interleukin-4-receptor α-chain-deletion constructs in both Ba/F3 cells and COS-7 cells, we show that all its cytoplasmic tyrosine residues can be removed without affecting the capability of the receptor complex to trigger STAT6 function with regard to tyrosine phosphorylation, DNA binding, and specific gene transcription. The activation of both STAT6 and janus kinase 1 (JAK1) by the interleukin-4 receptor was completely abolished by disruption of the membrane-proximal ’box 1' motif in the interleukin-4 receptor α chain. Our results indicate a redundant role of the previously defined phosphotyrosine-containing STAT6 docking site and suggest a mechanism of immediate activation of STAT6 by receptor-associated janus kinase(s). In addition, we demonstrate that dominant negative versions of both interleukin-4 receptor subunits are able to block interleukin-4 induced signalling via STAT6. [ABSTRACT FROM AUTHOR]
- Published
- 1998
- Full Text
- View/download PDF
7. Editorial: Cytokines in liver diseases.
- Author
-
Ilangumaran, Subburaj, Moriggl, Richard, and Kalvakolanu, Dhan V.
- Subjects
- *
LIVER diseases , *HEPATITIS A vaccines , *ANTI-vaccination movement , *FATTY liver , *CYTOKINES , *BLOOD proteins , *INTERLEUKIN-8 - Abstract
This special issue on 'Cytokines in Liver Diseases' was inspired by many talks and presentations on liver cancer during the 2nd Aegean Conference on Cytokine Signaling in Cancer (ACCSC) held at Heraklion, Crete, Greece on May 30–June 04, 2017 (Cytokine 2018, 108: 225–231). The liver is the biggest blood filtration and detoxification unit, and is a vital metabolic organ. Being constantly exposed to potentially harmful dietary chemicals, drugs, alcohol abuse and pathogens, the liver displays an extraordinary capacity to repair tissue damage and to regenerate. Moreover, only a healthy liver can provide the vast majority of plasma proteins, plus serving as a key organ for body homeostasis and metabolic fitness. Occasionally, the liver may have to deal with chronic damage inflicted by hepatotropic infections such as hepatitis viruses and metabolic derangements caused by obesity and the consequent metabolic syndrome. Overwhelming the natural defenses of the liver can compromise its vital functions and this can lead to more severe liver disease such as fibrosis that may progress towards cirrhosis and eventually to hepatocellular carcinoma (HCC). However, in obesity, a worldwide crisis that has been developing during the last few decades, HCC can develop in the fatty liver bypassing the fibrosis and cirrhosis stages. With the availability of effective therapies and vaccination strategies for hepatitis viruses, over nutrition has become the biggest new threat for a healthy liver. Cytokines and chemokines play a key role in the initiation and perpetuation of acute and chronic injury to the liver, and thus they contribute to most liver pathologies. The topic of cytokines in liver diseases is so vast that it cannot be adequately covered in this special issue. However, we have attempted to provide a glimpse of hot topics through comprehensive reviews and a few accompanying original articles on key research areas. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Tumor target amplification: Implications for nano drug delivery systems.
- Author
-
Seidi, Khaled, Neubauer, Heidi A., Moriggl, Richard, Jahanban-Esfahlan, Rana, and Javaheri, Tahereh
- Subjects
- *
DRUG delivery systems , *TUMORS , *CANCER cells , *GENE expression , *CANCER treatment , *LIGANDS (Biochemistry) - Abstract
Tumor cells overexpress surface markers which are absent from normal cells. These tumor-restricted antigenic signatures are a fundamental basis for distinguishing on-target from off-target cells for ligand-directed targeting of cancer cells. Unfortunately, tumor heterogeneity impedes the establishment of a solid expression pattern for a given target marker, leading to drastic changes in quality (availability) and quantity (number) of the target. Consequently, a subset of cancer cells remains untargeted during the course of treatment, which subsequently promotes drug-resistance and cancer relapse. Since target inefficiency is only problematic for cancer treatment and not for treatment of other pathological conditions such as viral/bacterial infections, target amplification or the generation of novel targets is key to providing eligible antigenic markers for effective targeted therapy. This review summarizes the limitations of current ligand-directed targeting strategies and provides a comprehensive overview of tumor target amplification strategies, including self-amplifying systems, dual targeting, artificial markers and peptide modification. We also discuss the therapeutic and diagnostic potential of these approaches, the underlying mechanism(s) and established methodologies, mostly in the context of different nanodelivery systems, to facilitate more effective ligand-directed cancer cell monitoring and targeting. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
9. Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes.
- Author
-
Valent, Peter, Klion, Amy D., Roufosse, Florence, Simon, Dagmar, Metzgeroth, Georgia, Leiferman, Kristin M., Schwaab, Juliana, Butterfield, Joseph H., Sperr, Wolfgang R., Sotlar, Karl, Vandenberghe, Peter, Hoermann, Gregor, Haferlach, Torsten, Moriggl, Richard, George, Tracy I., Akin, Cem, Bochner, Bruce S., Gotlib, Jason, Reiter, Andreas, and Horny, Hans‐Peter
- Subjects
- *
EOSINOPHIL disorders , *HYPEREOSINOPHILIC syndrome , *CLONE cells , *HEMATOLOGIC malignancies , *CLINICAL pathology - Abstract
Eosinophilia and eosinophil activation are recurrent features in various reactive states and certain hematologic malignancies. In patients with hypereosinophilia (HE), HE‐induced organ damage is often encountered and may lead to the diagnosis of a hypereosinophilic syndrome (HES). A number of known mechanisms and etiologies contribute to the development of HE and HES. Based on these etiologies and the origin of eosinophils, HE and HES are divided into primary forms where eosinophils are clonal cells, reactive forms where an underlying reactive or neoplastic condition is detected and eosinophils are considered to be "non‐clonal" cells, and idiopathic HE and HES in which neither a clonal nor a reactive underlying pathology is detected. Since 2012, this classification and the related criteria have been widely accepted and regarded as standard. However, during the past few years, new developments in the field and an increasing number of markers and targets have created a need to update these criteria and the classification of HE and HES. To address this challenge, a Working Conference on eosinophil disorders was organized in 2021. In this conference, a panel of experts representing the relevant fields, including allergy, dermatology, hematology, immunology, laboratory medicine, and pathology, met and discussed new markers and concepts as well as refinements in definitions, criteria and classifications of HE and HES. The outcomes of this conference are presented in this article and should assist in the diagnosis and management of patients with HE and HES in daily practice and in the preparation and conduct of clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lymphoma.
- Author
-
Garcha, Harsimran Kaur, Nawar, Nabanita, Sorger, Helena, Erdogan, Fettah, Aung, Myint Myat Khine, Sedighi, Abootaleb, Manaswiyoungkul, Pimyupa, Seo, Hyuk-Soo, Schönefeldt, Susann, Pölöske, Daniel, Dhe-Paganon, Sirano, Neubauer, Heidi A., Mustjoki, Satu M., Herling, Marco, de Araujo, Elvin D., Moriggl, Richard, and Gunning, Patrick T.
- Subjects
- *
DRUG synergism , *DRUG efficacy , *HEMATOLOGIC malignancies , *LYMPHOMAS , *DEACETYLASES - Abstract
NK/T-cell lymphoma (NKTCL) and γδ T-cell non-Hodgkin lymphomas (γδ T-NHL) are highly aggressive lymphomas that lack rationally designed therapies and rely on repurposed chemotherapeutics from other hematological cancers. Histone deacetylases (HDACs) have been targeted in a range of malignancies, including T-cell lymphomas. This study represents exploratory findings of HDAC6 inhibition in NKTCL and γδ T-NHL through a second-generation inhibitor NN-429. With nanomolar in vitro HDAC6 potency and high in vitro and in cellulo selectivity for HDAC6, NN-429 also exhibited long residence time and improved pharmacokinetic properties in contrast to older generation inhibitors. Following unique selective cytotoxicity towards γδ T-NHL and NKTCL, NN-429 demonstrated a synergistic relationship with the clinical agent etoposide and potential synergies with doxorubicin, cytarabine, and SNS-032 in these disease models, opening an avenue for combination treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia.
- Author
-
Pham, Ha Thi Thanh, Hengstschläger, Markus, and Moriggl, Richard
- Subjects
- *
GENETIC mutation , *LEUKEMIA , *LYMPHOMAS , *HEMATOPOIETIC stem cells , *TRANSGENIC mice , *LABORATORY mice , *PATIENTS , *T cell tumors - Abstract
The somatic hot spot mutation STAT5BN642H was found in many T cell leukemia/lymphoma patients. We generated and analyzed a transgenic mouse model with hematopoietic STAT5BN642H expression that caused aggressive T-cell leukemia/lymphomas. Herein, we discuss the scientific merit of our model and its relevance for pre-clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Adipocyte STAT5 deficiency does not affect blood glucose homeostasis in obese mice.
- Author
-
Beghini, Marianna, Wagner, Theresia, Luca, Andreea Corina, Metz, Matthäus, Kaltenecker, Doris, Spirk, Katrin, Hackl, Martina Theresa, Haybaeck, Johannes, Moriggl, Richard, Kautzky-Willer, Alexandra, Scherer, Thomas, and Fürnsinn, Clemens
- Subjects
- *
HOMEOSTASIS , *STAT proteins , *FAT cells , *BLOOD sugar , *WEIGHT gain , *FAT - Abstract
The aim of this study was to investigate whether the lack of signal transducer and activator of transcription 5 (STAT5) in mature adipocytes of obese mice (Stat5Adipoq mice) improves glucose and lipid metabolism as previously observed in lean mice. Male Stat5Adipoq mice and their wild type (WT) littermates were fed high-fat diet (HFD). Effects of adipocyte STAT5 deficiency on adiposity as well as on glucose and lipid metabolism were determined under ad libitum feeding and after weight loss induced by calorie restriction. Compared to WT mice, obese Stat5Adipoq mice showed modestly accelerated weight gain and blunted depletion of fat stores under calorie restriction (reduction in % body fat after 3 weeks: WT, -9.3±1.1, vs Stat5Adipoq, -5.9±0.8, p = 0.04). No differences were observed between Stat5Adipoq and WT mice with regard to parameters of glucose and lipid metabolism including basal glycaemia, glucose tolerance, and plasma triglycerides. In conclusion, STAT5 deficiency in the adipocyte of HFD-fed obese mice was associated with increased fat accumulation. In contrast to previous findings in lean mice, however, lipid accumulation was not associated with any improvement in glucose and lipid metabolism. Our results do not support adipocyte STAT5 as a promising target for the treatment of obesity-associated metabolic derangements. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
13. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy.
- Author
-
Tuckermann, Jan P., Kleiman, Anna, Moriggl, Richard, Spanbroek, Rainer, Neumann, Anita, Illing, Anett, Clausen, Björn E., Stride, Brenda, Förster, Irmgard, Habenicht, Andreas J. R., Reichardt, Holger M., Tronche, François, Schmid, Wolfgang, and Schütz, Günther
- Subjects
- *
GLUCOCORTICOIDS , *ALLERGIES , *MACROPHAGES , *NEUTROPHILS , *CYTOKINES , *IMMUNOSUPPRESSION - Abstract
Glucocorticoids (GCs) are widely used in the treatment of allergic skin conditions despite having numerous side effects. Here we use Cre/loxP-engineered tissue- and cell-specific and function-selective GC receptor (GR) mutant mice to identify responsive cell types and molecular mechanisms underlying the antiinflammatory activity of GCs in contact hypersensitivity (CHS). CHS was repressed by GCs only at the challenge phase, i.e., during reexposure to the hapten. Inactivation of the GR gene in keratinocytes or T cells of mutant mice did not attenuate the effects of GCs, but its ablation in macrophages and neutrophils abolished downregulation of the inflammatory response. Moreover, mice expressing a DNA binding—defective GR were also resistant to GC treatment. The persistent infiltration of macrophages and neutrophils in these mice is explained by an impaired repression of inflammatory cytokines and chemokines such as IL-1β, monocyte chemoattractant protein-1, macrophage inflammatory protein-2, and IFN-γ—inducible protein 10. In contrast TNF-α repression remained intact. Consequently, injection of recombinant proteins of these cytokines and chemokines partially reversed suppression of CHS by GCs. These studies provide evidence that in contact allergy, therapeutic action of corticosteroids is in macrophages and neutrophils and that dimerization GR is required. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
14. STAT1 acts as a tumor promoter for leukemia development
- Author
-
Kovacic, Boris, Stoiber, Dagmar, Moriggl, Richard, Weisz, Eva, Ott, René G., Kreibich, Rita, Levy, David E., Beug, Hartmut, Freissmuth, Michael, and Sexl, Veronika
- Subjects
- *
TUMORS , *LEUKEMIA , *MICE , *CANCER cells , *PROTEINS - Abstract
Summary: The tumor suppressor STAT1 is considered a key regulator of the surveillance of developing tumors. Here, we describe an unexpected tumor-promoting role for STAT1 in leukemia. STAT1−/− mice are partially protected from leukemia development, and STAT1−/− tumor cells induce leukemia in RAG2−/− and immunocompetent mice with increased latency. The low MHC class I protein levels of STAT1−/− tumor cells enable efficient NK cell lysis and account for the enhanced tumor clearance. Strikingly, STAT1−/− tumor cells acquire increased MHC class I expression upon leukemia progression. These findings define STAT1 as a tumor promoter in leukemia development. Furthermore, we describe the upregulation of MHC class I expression as a general mechanism that allows for the escape of hematopoietic malignancies from immune surveillance. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
15. Autocrine PDGFR signaling promotes mammary cancer metastasis.
- Author
-
Jechlinger, Martin, Sommer, Andreas, Moriggl, Richard, Seither, Peter, Kraut, Norbert, Capodiecci, Paola, Donovan, Michael, Cordon-Cardo, Carlos, Beug, Hartmut, and Grünert, Stefan
- Subjects
- *
METASTASIS , *PATHOLOGY , *CANCER invasiveness , *CELL death , *APOPTOSIS , *THERAPEUTICS - Abstract
Metastasis is the major cause of cancer morbidity, but strategies for direct interference with invasion processes are lacking. Dedifferentiated, late-stage tumor cells secrete multiple factors that represent attractive targets for therapeutic intervention. Here we show that metastatic potential of oncogenic mammary epithelial cells requires an autocrine PDGF/PDGFR loop, which is established as a consequence of TGF-β-induced epithelial-mesenchymal transition (EMT), a faithful in vitro correlate of metastasis. The cooperation of autocrine PDGFR signaling with oncogenic Ras hyperactivates PI3K and is required for survival during EMT. Autocrine PDGFR signaling also contributes to maintenance of EMT, possibly through activation of STAT1 and other distinct pathways. Inhibition of PDGFR signaling interfered with EMT and caused apoptosis in murine and human mammary carcinoma cell lines. Consequently, overexpression of a dominant-negative PDGFR or application of the established cancer drug STI571 interfered with experimental metastasis in mice. Similarly, in mouse mammary tumor virus-Neu (MMTV-Neu) transgenic mice, TGF-β enhanced metastasis of mammary tumors, induced EMT, and elevated PDGFR signaling. Finally, expression of PDGFRα and -β correlated with invasive behavior in human mammary carcinomas. Thus, autocrine PDGFR signaling plays an essential role during cancer progression, suggesting a novel application of STI571 to therapeutically interfere with metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
16. A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: Insights from gene expression profiling
- Author
-
Gatzka, Martina, Piekorz, Roland, Moriggl, Richard, Rawlings, Jason, and Ihle, James N.
- Subjects
- *
APOPTOSIS , *GENE expression , *PROTEINS , *TRANSCRIPTION factors - Abstract
Abstract: Activation of the transcription factors STAT5A and STAT5B by JAK1 and JAK3 tyrosine kinases is a key event in downstream signaling of γc (common gamma chain)-family cytokine receptors in lymphoid cells. STAT5A/B-deficiency in mice causes, among other consequences, a reduced size and altered composition of the peripheral T-cell pool with predominance of an activated or memory-like population (CD4+/CD44high/CD62Llow) and a proliferative deficiency following antigenic stimulation and subsequent IL-2 treatment. To further elucidate the critical function of STAT5A/B in homeostasis and activation of murine naïve peripheral T-lymphocytes, we have analyzed global gene expression of STAT5A/B-deficient versus wild-type splenic T-cells by profiling with high-density oligonucleotide arrays (Affymetrix). Comparison of (1) basal gene expression of untreated peripheral STAT5A/B-deficient and control T-cells and (2) immediate early gene induction upon in vitro stimulation of either population with IL-2 has revealed differential expression of a broad range of genes potentially contributing to the defects of STAT5A/B deficient T-cells. In the context of enhanced apoptotic rates of STAT5A/B−/−-T-cells in vivo and upon TCR-stimulation in culture our data suggest a role for STAT5 in post-activation survival beyond regulation of antiapoptotic Bcl-2 proteins and hence provide new insights into the nature of the late proliferative block in the T-cell compartment caused by STAT5-deficiency. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
17. Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth.
- Author
-
Corvinus, Florian M., Orth, Carina, Moriggl, Richard, Tsareva, Svetlana A., Wagner, Stefan, Pfitzner, Edith B., Baus, Daniela, Kaufmann, Roland, Huber, Lukas A., Zatloukal, Kurt, Beug, Hartmut, Öhlschläger, Peter, Schütz, Alexander, Halbhuber, Karl-Jürgen, and Friedrich, Karlheinz
- Subjects
- *
COLON cancer , *MORTALITY , *CELLULAR signal transduction , *CANCER cells , *LYMPHOCYTES , *CELL lines - Abstract
Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries. It has so far been molecularly defined mainly by alterations of the Wnt pathway. We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC. Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium. Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture. However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation. STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-negative variant impaired IL-6-driven proliferation. Blockade of STAT3 activation in CRC-derived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
18. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth.
- Author
-
Tronche, Francois, Opherk, Christian, Moriggl, Richard, Kellendonk, Christoph, Reimann, Andreas, Schwake, Lukas, Reichardt, Holger M., Stangl, Katharina, Gau, Daniel, Hoeflich, Andreas, Beug, Hartmut, Schmid, Wolfgang, and Schütz, Günther
- Subjects
- *
GLUCOCORTICOIDS , *LIVER cells , *HORMONES , *CELL receptors , *DNA , *TRANSCRIPTION factors , *PHYSIOLOGICAL control systems , *CELL physiology - Abstract
Mice carrying a hepatocyte-specific inactivation of the glucorticoid receptor (GR) gene show a dramatic reduction in body size. Growth hormone signaling mediated by the Stat5 transcription factors is impaired. We show that Stat5 proteins physically interact with GR and GR is present in vivo on Stat5-dependent IGF-I and ALS regulatory regions. Interestingly, mice with a DNA-binding-deficient GR but an unaltered ability to interact with STATS (GRdim/dim) have a normal body size and normal levels of Stat5-dependent mRNAs. These findings strongly support the model in which GR acts as a coactivator for Stat5-dependent transcription upon GH stimulation and reveal an essential role of hepatic GR in the control of body growth. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
19. A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation.
- Author
-
Surbek, Marta, Tse, William, Moriggl, Richard, and Han, Xiaonan
- Subjects
- *
INTESTINAL infections , *HOMEOSTASIS , *EPITHELIAL cells , *INTESTINAL injuries , *STEM cells , *GROWTH factors , *WOUND healing , *INTESTINAL mucosa - Abstract
• The review discusses major advances of JAK/STAT5 signaling in intestinal immunity. • The review discusses STAT5 functions in epithelial cell repair upon injury. • The review highlights gaps in the research of intestinal STAT5 function. Cytokines, growth factors or hormones take action through the JAK/STAT5 signaling pathway, which plays a critical role in regulating the intestinal response to infection and inflammation. However, the way in which STAT5 regulates intestinal epithelial compartment is largely ignored due to the lack of genetic tools for proper exploration and because the two STAT5 transcription factors (STAT5A and STAT5B) have some redundant but also distinct functions. In this review article, by focusing on STAT5 functions in the intestinal undifferentiated and differentiated epithelia, we discuss major advances of the growth factor/cytokine-JAK/STAT5 research in view of intestinal mucosal inflammation and immunity. We highlight the gap in the research of the intestinal STAT5 signaling to anticipate the gastrointestinal explorative insights. Furthermore, we address the critical questions to illuminate how STAT5 signaling influences intestinal epithelial cell differentiation and stem cell regeneration during homeostasis and injury. Overall, our article provides a centric view of the relevance of the relationship between chronic inflammatory diseases and JAK/STAT5 pathway and it also gives an example of how chronic infection and inflammation pirate STAT5 signaling to worsen intestinal injuries. Importantly, our review suggests how to protect a wound healing from gastrointestinal diseases by modulating intestinal STAT5. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Opioids drive breast cancer metastasis through the δ-opioid receptor and oncogenic STAT3.
- Author
-
Tripolt, Sabrina, Neubauer, Heidi A., Knab, Vanessa M., Elmer, Dominik P., Aberger, Fritz, Moriggl, Richard, and Fux, Daniela A.
- Subjects
- *
METASTATIC breast cancer , *CANCER cell migration , *NALTREXONE , *EPITHELIAL-mesenchymal transition , *BREAST cancer prognosis , *CANCER invasiveness , *CADHERINS - Abstract
The opioid crisis of pain medication bears risks from addiction to cancer progression, but little experimental evidence exists. Expression of δ-opioid receptors (DORs) correlates with poor prognosis for breast cancer patients, but mechanistic insights into oncogenic signaling mechanisms of opioid-triggered cancer progression are lacking. We show that orthotopic transplant models using human or murine breast cancer cells displayed enhanced metastasis upon opioid-induced DOR stimulation. Interestingly, opioid-exposed breast cancer cells showed enhanced migration and strong STAT3 activation, which was efficiently blocked by a DOR-antagonist. Furthermore, opioid treatment resulted in down-regulation of E-Cadherin and increased expression of epithelial-mesenchymal transition markers. Notably, STAT3 knockdown or upstream inhibition through the JAK1/2 kinase inhibitor ruxolitinib prevented opioid-induced breast cancer cell metastasis and migration in vitro and in vivo. We conclude on a novel mechanism whereby opioid-triggered breast cancer metastasis occurs via oncogenic JAK1/2-STAT3 signaling to promote epithelial-mesenchymal transition. These findings emphasize the importance of selective and restricted opioid use, as well as the need for safer pain medication that does not activate these oncogenic pathways. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. Advances in covalent kinase inhibitors.
- Author
-
Abdeldayem, Ayah, Raouf, Yasir S., Constantinescu, Stefan N., Moriggl, Richard, and Gunning, Patrick T.
- Subjects
- *
KINASE inhibitors , *ELECTROPHILES , *TREND analysis - Abstract
Over the past decade, covalent kinase inhibitors (CKI) have seen a resurgence in drug discovery. Covalency affords a unique set of advantages as well as challenges relative to their non-covalent counterpart. After reversible protein target recognition and binding, covalent inhibitors irreversibly modify a proximal nucleophilic residue on the protein via reaction with an electrophile. To date, the acrylamide group remains the predominantly employed electrophile in CKI development, with its incorporation in the majority of clinical candidates and FDA approved covalent therapies. Nonetheless, in recent years considerable efforts have ensued to characterize alternative electrophiles that exhibit irreversible or reversibly covalent binding mechanisms towards cysteine thiols and other amino acids. This review article provides a comprehensive overview of CKIs reported in the literature over a decade period, 2007–2018. Emphasis is placed on the rationale behind warhead choice, optimization approach, and inhibitor design. Current FDA approved CKIs are also highlighted, in addition to a detailed analysis of the common trends and themes observed within the listed data set. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. The neonatal microenvironment programs innate γδ T cells through the transcription factor STAT5.
- Author
-
Kadekar, Darshana, Agerholm, Rasmus, Rizk, John, Neubauer, Heidi A., Suske, Tobias, Maurer, Barbara, Viñals, Monica Torrellas, Comelli, Elena M., Taibi, Amel, Moriggl, Richard, and Bekiaris, Vasileios
- Subjects
- *
ANIMAL experimentation , *ANIMAL populations , *CARRIER proteins , *CELL physiology , *CELL receptors , *COMPARATIVE studies , *CYTOKINES , *IMMUNITY , *INTESTINES , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *RESEARCH , *T cells , *EVALUATION research - Abstract
IL-17-producing RORγt+ γδ T cells (γδT17 cells) are innate lymphocytes that participate in type 3 immune responses during infection and inflammation. Herein, we show that γδT17 cells rapidly proliferate within neonatal lymph nodes and gut, where, upon entry, they upregulate T-bet and coexpress IL-17, IL-22, and IFN-γ in a STAT3- and retinoic acid-dependent manner. Neonatal expansion was halted in mice conditionally deficient in STAT5, and its loss resulted in γδT17 cell depletion from all adult organs. Hyperactive STAT5 mutant mice showed that the STAT5A homolog had a dominant role over STAT5B in promoting γδT17 cell expansion and downregulating gut-associated T-bet. In contrast, STAT5B preferentially expanded IFN-γ-producing γδ populations, implying a previously unknown differential role of STAT5 gene products in lymphocyte lineage regulation. Importantly, mice lacking γδT17 cells as a result of STAT5 deficiency displayed a profound resistance to experimental autoimmune encephalomyelitis. Our data identify that the neonatal microenvironment in combination with STAT5 is critical for post-thymic γδT17 development and tissue-specific imprinting, which is essential for infection and autoimmunity. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia.
- Author
-
Pham, Ha Thi Thanh, Hengstschläger, Markus, and Moriggl, Richard
- Subjects
- *
T cells , *LEUKEMIA , *LYMPHOMAS , *HEMATOPOIESIS , *SOMATIC cells - Abstract
The somatic hot spot mutation STAT5BN642H was found in many T cell leukemia/lymphoma patients. We generated and analyzed a transgenic mouse model with hematopoietic STAT5BN642H expression that caused aggressive T-cell leukemia/lymphomas. Herein, we discuss the scientific merit of our model and its relevance for pre-clinical studies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Pharmacologic IL-6Rα inhibition in cholangiocarcinoma promotes cancer cell growth and survival.
- Author
-
Kleinegger, Florian, Hofer, Eva, Wodlej, Christina, Golob-Schwarzl, Nicole, Birkl-Toeglhofer, Anna Maria, Stallinger, Alexander, Petzold, Johannes, Orlova, Anna, Krassnig, Stefanie, Reihs, Robert, Niedrist, Tobias, Mangge, Harald, Park, Young Nyun, Thalhammer, Michael, Aigelsreiter, Ariane, Lax, Sigurd, Garbers, Christoph, Fickert, Peter, Rose-John, Stefan, and Moriggl, Richard
- Subjects
- *
CHOLANGIOCARCINOMA , *BILE duct diseases , *BILE duct adenocarcinoma , *GALLBLADDER ,BILIARY tract cancer - Abstract
Abstract Biliary tract cancer (BTC) represents a malignant tumor of the biliary tract including cholangiocarcinoma (CCA) and the carcinoma of the gallbladder (GBC) with a 5-year survival rate between 5 and 18% due to late diagnosis and rapid disease progression. Chronic inflammation is one of the main risk factors for CCA and GBC in particular. IL-6, as a mediator of inflammation, can act through a membrane-bound receptor alpha-chain (mIL-6R, "IL-6 classic signaling") or via soluble forms (sIL-6R, "IL-6 trans-signaling"). However, little is known about the impact on cellular responses of IL-6 trans-signaling on BTC. We analyzed primary tumors as whole sections and as tissue microarrays, and also searched The Cancer Genome Atlas database. Compared to non-neoplastic, non-inflamed gallbladder tissue, IL-6Rα was downregulated in GBC, and this correlated with the patients' overall survival. Furthermore, different CCA cell lines and compounds for activation (IL-6 and Hyper-IL-6) or inhibition (Tocilizumab and sgp130Fc) of IL-6 classic signaling and trans-signaling were used to determine their effects on cellular processes between the two modes of IL-6 signaling. Inhibition of IL-6 trans-signaling by sgp130Fc reduced CCA cell line viability and apoptosis, whereas migration and proliferation were increased. We conclude that IL-6Rα expression is a good prognostic marker for GBC, and that the blocking of IL-6 trans-signaling and activation of IL-6 classic signaling have tumor promoting activity. These findings warrant the exclusion of patients with GBC or other malignancies associated with bile metabolism from IL-6R inhibitor therapy. Highlights • IL-6Rα expression correlates with overall survival in GBC. • IL-6Rα is downregulated in GBC. • Blocking IL-6 trans-signaling promotes CCA in vitro. • Activation of IL-6 classic signaling promotes CCA in vitro. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.
- Author
-
Keller, Alexandra, Wingelhofer, Bettina, Peter, Barbara, Bauer, Karin, Berger, Daniela, Gamperl, Susanne, Reifinger, Martin, Cerny-Reiterer, Sabine, Moriggl, Richard, Willmann, Michael, Valent, Peter, and Hadzijusufovic, Emir
- Subjects
- *
TUMORS in animals , *CANCER in dogs , *MAST cell tumors , *BENIGN tumors , *METASTASIS - Abstract
Background: Mastocytoma are frequently diagnosed cutaneous neoplasms in dogs. In nonresectable mastocytoma patients, novel targeted drugs are often applied. The transcription factor STAT5 has been implicated in the survival of human neoplastic mast cells (MC). Our study evaluated the JAK2/STAT5 pathway as a novel target in canine mastocytoma. Materials and Methods: We employed inhibitors of JAK2 (R763, TG101348, AZD1480, ruxolitinib) and STAT5 (pimozide, piceatannol) and evaluated their effects on 2 mastocytoma cell lines, C2 and NI-1. Results: Activated JAK2 and STAT5 were detected in both cell lines. The drugs applied were found to inhibit proliferation and survival in these cells with the following rank-order of potency: R763 > TG101348 > AZD1480 > pimozide > ruxolitinib > piceatannol. Moreover, synergistic anti-neoplastic effects were obtained by combining pimozide with KIT-targeting drugs (toceranib, masitinib, nilotinib, midostaurin) in NI-1 cells. Conclusion: The JAK2/STAT5 pathway is a novel potential target of therapy in canine mastocytoma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. AKT3 drives adenoid cystic carcinoma development in salivary glands.
- Author
-
Zboray, Katalin, Mohrherr, Julian, Stiedl, Patricia, Pranz, Klemens, Wandruszka, Laura, Grabner, Beatrice, Eferl, Robert, Moriggl, Richard, Stoiber, Dagmar, Sakamoto, Kazuhito, Wagner, Kay‐Uwe, Popper, Helmut, Casanova, Emilio, and Moll, Herwig P.
- Subjects
- *
ADENOID cystic carcinoma , *SALIVARY gland cancer , *TUMORS , *SALIVARY gland diseases , *CANCER chemotherapy , *LABORATORY rats - Abstract
Abstract: Salivary gland cancer is an aggressive and painful cancer, but a rare tumor type accounting for only ~0.5% of cancer cases. Tumors of the salivary gland exhibit heterogeneous histologic and genetic features and they are subdivided into different subtypes, with adenoid cystic carcinomas (ACC) being one of the most abundant. Treatment of ACC patients is afflicted by high recurrence rates, the high potential of the tumors to metastasize, as well as the poor response of ACC to chemotherapy. A prerequisite for the development of targeted therapies is insightful genetic information for driver core cancer pathways. Here, we developed a transgenic mouse model toward establishment of a preclinical model. There is currently no available mouse model for adenoid cystic carcinomas as a rare disease entity to serve as a test system to block salivary gland tumors with targeted therapy. Based on tumor genomic data of ACC patients, a key role for the activation of the PI3K‐AKT‐mTOR pathway was suggested in tumors of secretory glands. Therefore, we investigated the role of
Akt3 expression in tumorigenesis and report thatAkt3 overexpression results in ACC of salivary glands with 100% penetrance, while abrogation of transgenicAkt3 expression could revert the phenotype. In summary, our findings validate a novel mouse model to study ACC and highlight the druggable potential of AKT3 in the treatment of salivary gland patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
27. First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
- Author
-
Boidol, Bernd, Kornauth, Christoph, van der Kouwe, Emiel, Prutsch, Nicole, Kazianka, Lukas, Gültekin, Sinan, Hoermann, Gregor, Mayerhoefer, Marius E., Hopfinger, Georg, Hauswirth, Alexander, Panny, Michael, Marie-Bernadette, Aretin, Hilgarth, Bernadette, Sperr, Wolfgang R., Valent, Peter, Simonitsch-Klupp, Ingrid, Moriggl, Richard, Merkel, Olaf, Kenner, Lukas, and Jäger, Ulrich
- Subjects
- *
BCL-2 proteins , *T-cell lymphoma , *LEUKEMIA , *ACUTE myeloid leukemia - Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive T-lymphoid malignancy usually refractory to current treatment strategies and associated with short overall survival. By applying next-generation functional testing of primary patient-derived lymphoma cells using a library of 106 US Food and Drug Administration (FDA)-approved anticancer drugs or compounds currently in clinical development, we set out to identify novel effective treatments for T-PLL patients. We found that the B-cell lymphoma 2 (BCL-2) inhibitor venetoclax (ABT-199) demonstrated the strongest T-PLL-specific response when comparing individual ex vivo drug response in 86 patients with refractory hematologic malignancies. Mechanistically, responses to venetoclax correlated with protein expression of BCL-2 but not with expression of the BCL-2 family members myeloid cell leukemia1(MCL-1) and BCL-XL in lymphoma cells. BCL-2 expression was inversely correlated with the expression of MCL-1. Based on the ex vivo responses, venetoclax treatment was commenced in 2 late-stage refractory T-PLL patients resulting in clinical responses. Our findings demonstrate first evidence of single-agent activity of venetoclax both ex vivo and in humans, offering a novel agent in T-PLL. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Expansion of BCR/ ABL1+ cells requires PAK2 but not PAK1.
- Author
-
Edlinger, Leo, Berger‐Becvar, Angelika, Menzl, Ingeborg, Hoermann, Gregor, Greiner, Georg, Grundschober, Eva, Bago‐Horvath, Zsuzsanna, Al‐Zoughbi, Wael, Hoefler, Gerald, Brostjan, Christine, Gille, Lars, Moriggl, Richard, Spittler, Andreas, Sexl, Veronika, and Hoelbl‐Kovacic, Andrea
- Subjects
- *
P21 gene , *KINASES , *CANCER cells , *CANCER prognosis , *TUMORS , *LEUKEMIA - Abstract
The p21-activated kinases ( PAKs) are key nodes in oncogenic signalling pathways controlling growth, survival, and motility of cancer cells. Their activity is increased in many human cancers and is associated with poor prognosis. To date, PAK deregulation has mainly been studied in solid tumours, where PAK1 and PAK4 are the main isoforms deregulated. We show that PAK1 and PAK2 are the critical isoforms in a BCR/ ABL1+ haematopoietic malignancy. In suspension, leukaemic cells deficient for PAK1 and PAK2 undergo apoptosis, while the loss of either protein is well tolerated. Transfer of medium conditioned by sh PAK2- but not sh PAK1-expressing leukaemic cells interferes with endothelial cell growth. We found that leukaemic cells produce exosomes containing PAK2. Transfer of isolated exosomes supports endothelial cell proliferation. In parallel, we found that leukaemic cells explicitly require PAK2 to grow towards an extracellular matrix. PAK2-deficient cells fail to form colonies in methylcellulose and to induce lymphomas in vivo. PAK2 might therefore be the critical isoform in leukaemic cells by controlling tumour growth in a dual manner: vascularization via exosome-mediated transfer to endothelial cells and remodelling of the extracellular matrix. This finding suggests that the PAK2 isoform represents a promising target for the treatment of haematological diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. When the guardian sleeps: Reactivation of the p53 pathway in cancer.
- Author
-
Merkel, Olaf, Taylor, Ninon, Prutsch, Nicole, Staber, Philipp B., Moriggl, Richard, Turner, Suzanne D., and Kenner, Lukas
- Subjects
- *
P53 antioncogene , *TUMOR growth , *GENE therapy , *GENETIC mutation , *CANCER treatment - Abstract
The p53 tumor suppressor is inactivated in most cancers, thus suggesting that loss of p53 is a prerequisite for tumor growth. Therefore, its reintroduction through different means bears great clinical potential. After a brief introduction to current knowledge of p53 and its regulation by the ubiquitin-ligases MDM2/MDMX and post-translational modifications, we will discuss small molecules that are able to reactivate specific, frequently observed mutant forms of p53 and their applicability for clinical purposes. Many malignancies display amplification of MDM genes encoding negative regulators of p53 and therefore much effort to date has concentrated on the development of molecules that inhibit MDM2, the most advanced of which are being tested in clinical trials for sarcoma, glioblastoma, bladder cancer and lung adenocarcinoma. These will be discussed as will recent findings of MDMX inhibitors: these are of special importance as it has been shown that cancers that become resistant to MDM2 inhibitors often amplify MDM4 . Finally, we will also touch on gene therapy and vaccination approaches; the former of which aims to replace mutated TP53 and the latter whose goal is to activate the body’s immune system toward mutant p53 expressing cells. Besides the obvious importance of MDM2 and MDMX expression for regulation of p53, other regulatory factors should not be underestimated and are also described. Despite the beauty of the concept, the past years have shown that many obstacles have to be overcome to bring p53 reactivation to the clinic on a broad scale, and it is likely that in most cases it will be part of a combined therapeutic approach. However, improving current p53 targeted molecules and finding the best therapy partners will clearly impact the future of cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition.
- Author
-
Mueller, Kristina M., Hartmann, Kerstin, Kaltenecker, Doris, Vettorazzi, Sabine, Bauer, Mandy, Mauser, Lea, Amann, Sabine, Jall, Sigrid, Fischer, Katrin, Esterbauer, Harald, Müller, Timo D., Tschöp, Matthias H., Magnes, Christoph, Haybaeck, Johannes, Scherer, Thomas, Bordag, Natalie, Tuckermann, Jan P., and Moriggl, Richard
- Subjects
- *
GLUCOCORTICOIDS , *ENERGY metabolism , *PATHOLOGICAL physiology , *METABOLOMICS , *OBESITY , *FAT cells , *ADIPOSE tissues , *AGING , *ANIMAL experimentation , *BETA adrenoceptors , *BIOCHEMISTRY , *HUMAN body composition , *CELL receptors , *CELLULAR signal transduction , *DIET , *FASTING , *FATTY liver , *FOOD habits , *GENETIC disorders , *HYPERTROPHY , *INSULIN , *LIPID metabolism disorders , *LIQUID chromatography , *LIVER , *MASS spectrometry , *MICE , *WESTERN immunoblotting - Abstract
Glucocorticoids (GCs) are important regulators of systemic energy metabolism, and aberrant GC action is linked to metabolic dysfunctions. Yet, the extent to which normal and pathophysiological energy metabolism depend on the GC receptor (GR) in adipocytes remains unclear. Here, we demonstrate that adipocyte GR deficiency in mice significantly impacts systemic metabolism in different energetic states. Plasma metabolomics and biochemical analyses revealed a marked global effect of GR deficiency on systemic metabolite abundance and, thus, substrate partitioning in fed and fasted states. This correlated with a decreased lipolytic capacity of GR-deficient adipocytes under postabsorptive and fasting conditions, resulting from impaired signal transduction from β-adrenergic receptors to adenylate cyclase. Upon prolonged fasting, the impaired lipolytic response resulted in abnormal substrate utilization and lean mass wasting. Conversely, GR deficiency attenuated aging-/diet-associated obesity, adipocyte hypertrophy, and liver steatosis. Systemic glucose tolerance was improved in obese GR-deficient mice, which was associated with increased insulin signaling in muscle and adipose tissue. We conclude that the GR in adipocytes exerts central but diverging roles in the regulation of metabolic homeostasis depending on the energetic state. The adipocyte GR is indispensable for the feeding-fasting transition but also promotes adiposity and associated metabolic disorders in fat-fed and aged mice. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3.
- Author
-
Friedrich, Karlheinz, Dolznig, Helmut, Xiaonan Han, and Moriggl, Richard
- Subjects
- *
CARCINOMA , *CANCER invasiveness , *YIN-yang , *TRANSCRIPTION factors , *GENETICS of colon cancer , *COLON cancer treatment , *TUMOR suppressor genes ,ANIMAL models of tumors - Abstract
STAT1/STAT3 transcription factors are important regulators for development of normal, infected or inflammed cells. They are also critically involved in the progression of various malignant tumours, including epithelial-derived carcinomas. Here, we focus on colorectal cancer (CRC) insights for STAT1/3, where controversial functions for STAT3 were reported. For a long time STAT3 has been regarded as a driver of tumour malignancy and its activation was associated with negative clinical outcome. In contrast, STAT1 was generally viewed as an independent tumour suppressor and positive prognostic marker. Here we discuss the experimental evidence for the tight association and regulation of oncogenic STAT3 transcription kept at bay by nuclear STAT1. We summarise current research and describe cellular models of different STAT1/STAT3 expression ratios. STAT1/3 expression levels are influenced by the mutational status of carcinoma cells associated with nuclear unphosphorylated STAT1. Animal tumour models and results from in vitro experiments allow for the conclusion that both proteins interact as antagonistic transcription factors in CRC cells. These STATs steer also important processes during infection and inflammation that influence development and progression of CRC. The STAT1/3 interplay is important to understand gene regulation and we describe it here similar like the YIN/YANG dualism. Thus, we propose to evaluate both STAT1 and STAT3 expression patterns in cancers in a dual manner instead of regarding them as independent transcription factors. This conceptual dualistic view could advance diagnostic predictions in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
32. JAK-STAT signaling in cancer: From cytokines to non-coding genome.
- Author
-
Pencik, Jan, Pham, Ha Thi Thanh, Schmoellerl, Johannes, Javaheri, Tahereh, Schlederer, Michaela, Culig, Zoran, Merkel, Olaf, Moriggl, Richard, Grebien, Florian, and Kenner, Lukas
- Subjects
- *
JAK-STAT pathway , *HEMATOLOGIC malignancies , *PROSTATE cancer , *NON-coding DNA , *BIOMARKERS - Abstract
In the past decades, studies of the Janus kinases (JAKs) and signal transducers and activators of transcription (STATs) signaling have uncovered highly conserved programs linking cytokine signaling to the regulation of essential cellular mechanisms such as proliferation, invasion, survival, inflammation and immunity. Inhibitors of the JAK/STAT pathway are used for treatment of autoimmune diseases, such as rheumatoid arthritis or psoriasis. Aberrant JAK/STAT signaling has been identified to contribute to cancer progression and metastatic development. Targeting of JAK/STAT pathway is currently one of the most promising therapeutic strategies in prostate cancer (PCa), hematopoietic malignancies and sarcomas. Notably, newly identified regulators of JAK/STAT signaling, the non-coding RNAs transcripts and their role as important targets and potential clinical biomarkers are highlighted in this review. In addition to the established role of the JAK/STAT signaling pathway in traditional cytokine signaling the non-coding RNAs add yet another layer of hidden regulation and function. Understanding the crosstalk of non-coding RNA with JAK/STAT signaling in cancer is of critical importance and may result in better patient stratification not only in terms of prognosis but also in the context of therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus.
- Author
-
Birner, Peter, Heider, Susanne, Petzelbauer, Peter, Wolf, Peter, Kornauth, Christoph, Kuroll, Madeleine, Merkel, Olaf, Steiner, Günter, Kishimoto, Tadamitsu, Rose‐John, Stefan, Soleiman, Afschin, Moriggl, Richard, and Kenner, Lukas
- Subjects
- *
INTERLEUKIN-6 receptors , *PRECANCEROUS conditions , *AUTOANTIBODIES , *SYSTEMIC lupus erythematosus , *IMMUNOFLUORESCENCE - Abstract
Systemic lupus erythematosus ( SLE) is an autoimmune disease, characterized by antinuclear autoantibodies ( ANA) and immunocomplexes, commonly affecting kidneys, skin, heart, lung or even the brain. We have shown that JunBΔep mice develop a SLE phenotype linked to increased epidermal Interleukin ( IL)-6 secretion. Blocking of IL-6 receptor alpha ( IL-6R α) is considered as therapeutic strategy for the treatment of SLE. JunBΔep and wild-type mice were treated for short (5 weeks) or long term (21 weeks) with the IL-6R α-blocking antibody MR16-1. Skin and kidney of mice were investigated by histology and immunofluorescence, and in addition, kidneys were analysed by electron microscopy. Furthermore, soluble IL-6R ( sIL-6R), antihistone and antinucleosome antibodies levels were measured and associated with disease parameters. Treatment with MR16-1 resulted in significant improvement of SLE-like skin lesions in JunBΔep mice, compared to untreated mice. The sIL-6R amount upon long-term treatment with MR16-1 was significantly higher in JunBΔep versus untreated JunBΔep ( P = 0.034) or wild-type mice ( P = 0.034). MR16-1 treatment over these time spans did not significantly improve kidney pathology of immunoglobulin deposits causing impaired function. Significantly higher antihistone ( P = 0.028) and antinucleosome antibody levels ( P = 0.028) were measured in MR16-1-treated JunBΔep mice after treatment compared to levels before therapy. In conclusion, blockade of IL-6R α improves skin lesions in a murine SLE model, but does not have a beneficial effect on autoimmune-mediated kidney pathology. Inhibition of IL-6R signalling might be helpful in lupus cases with predominant skin involvement, but combinatorial treatment might be required to restrain autoantibodies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
34. Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
- Author
-
Weber, Axel, Borghouts, Corina, Brendel, Christian, Moriggl, Richard, Delis, Natalia, Brill, Boris, Vafaizadeh, Vida, and Groner, Bernd
- Subjects
- *
ANALYSIS of variance , *GENE expression , *POLYMERASE chain reaction , *RESEARCH funding , *STATISTICS , *WESTERN immunoblotting , *DATA analysis , *CHRONIC myeloid leukemia , *REVERSE transcriptase polymerase chain reaction , *DATA analysis software , *DESCRIPTIVE statistics , *FLUOROIMMUNOASSAY , *IN vitro studies - Abstract
Signal transducers and activators of transcription (Stats) play central roles in the conversion of extracellular signals, e.g., cytokines, hormones and growth factors, into tissue and cell type specific gene expression patterns. In normal cells, their signaling potential is strictly limited in extent and duration. The persistent activation of Stat3 or Stat5 is found in many human tumor cells and contributes to their growth and survival. Stat5 activation plays a pivotal role in nearly all hematological malignancies and occurs downstream of oncogenic kinases, e.g., Bcr-Abl in chronic myeloid leukemias (CML) and Jak2(V617F) in other myeloproliferative diseases (MPD). We defined the mechanisms through which Stat5 affects growth and survival of K562 cells, representative of Bcr-Abl positive CML, and HEL cells, representative for Jak2(V617F) positive acute erythroid leukemia. In our experiments we suppressed the protein expression levels of Stat5a and Stat5b through shRNA mediated downregulation and demonstrated the dependence of cell survival on the presence of Stat5. Alternatively, we interfered with the functional capacities of the Stat5 protein through the interaction with a Stat5 specific peptide ligand. This ligand is a Stat5 specific peptide aptamer construct which comprises a 12mer peptide integrated into a modified thioredoxin scaffold, S5-DBD-PA. The peptide sequence specifically recognizes the DNA binding domain (DBD) of Stat5. Complex formation of S5-DBD-PA with Stat5 causes a strong reduction of P-Stat5 in the nuclear fraction of Bcr-Abl-transformed K562 cells and a suppression of Stat5 target genes. Distinct Stat5 mediated survival mechanisms were detected in K562 and Jak2(V617F)-transformed HEL cells. Stat5 is activated in the nuclear and cytosolic compartments of K562 cells and the S5-DBD-PA inhibitor most likely affects the viability of Bcr-Abl+ K562 cells through the inhibition of canonical Stat5 induced target gene transcription. In HEL cells, Stat5 is predominantly present in the cytoplasm and the survival of the Jak2(V617F)+ HEL cells is impeded through the inhibition of the cytoplasmic functions of Stat5. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
35. Reliable Quantification of Protein Expression and Cellular Localization in Histological Sections.
- Author
-
Schlederer, Michaela, Mueller, Kristina M., Haybaeck, Johannes, Heider, Susanne, Huttary, Nicole, Rosner, Margit, Hengstschläger, Markus, Moriggl, Richard, Dolznig, Helmut, and Kenner, Lukas
- Subjects
- *
PROTEIN expression , *TUMORS , *BIOMARKERS , *CANCER treatment , *TREATMENT effectiveness , *IMMUNOHISTOCHEMISTRY , *PATIENTS - Abstract
In targeted therapy, patient tumors are analyzed for aberrant activations of core cancer pathways, monitored based on biomarker expression, to ensure efficient treatment. Thus, diagnosis and therapeutic decisions are often based on the status of biomarkers determined by immunohistochemistry in combination with other clinical parameters. Standard evaluation of cancer specimen by immunohistochemistry is frequently impeded by its dependence on subjective interpretation, showing considerable intra- and inter-observer variability. To make treatment decisions more reliable, automated image analysis is an attractive possibility to reproducibly quantify biomarker expression in patient tissue samples. We tested whether image analysis could detect subtle differences in protein expression levels. Gene dosage effects generate well-graded expression patterns for most gene-products, which vary by a factor of two between wildtype and haploinsufficient cells lacking one allele. We used conditional mouse models with deletion of the transcription factors Stat5ab in the liver as well Junb deletion in a T-cell lymphoma model. We quantified the expression of total or activated STAT5AB or JUNB protein in normal (Stat5ab+/+ or JunB+/+), hemizygous (Stat5ab+/Δ or JunB+/Δ) or knockout (Stat5abΔ/Δ or JunBΔ/Δ) settings. Image analysis was able to accurately detect hemizygosity at the protein level. Moreover, nuclear signals were distinguished from cytoplasmic expression and translocation of the transcription factors from the cytoplasm to the nucleus was reliably detected and quantified using image analysis. We demonstrate that image analysis supported pathologists to score nuclear STAT5AB expression levels in immunohistologically stained human hepatocellular patient samples and decreased inter-observer variability. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
36. Structural and mutational analysis of member-specific STAT functions.
- Author
-
Erdogan, Fettah, Qadree, Abdul K., Radu, Tudor B., Orlova, Anna, de Araujo, Elvin D., Israelian, Johan, Valent, Peter, Mustjoki, Satu M., Herling, Marco, Moriggl, Richard, and Gunning, Patrick T.
- Subjects
- *
STAT proteins , *GENE expression , *TARGETED drug delivery , *COMMUNICABLE diseases - Abstract
The STAT family of transcription factors control gene expression in response to signals from various stimulus. They display functions in diseases ranging from autoimmunity and chronic inflammatory disease to cancer and infectious disease. This work uses an approach informed by structural data to explore how domain-specific structural variations, post-translational modifications, and the cancer genome mutational landscape dictate STAT member-specific activities. We illustrated the structure-function relationship of STAT proteins and highlighted their effect on member-specific activity. We correlated disease-linked STAT mutations to the structure and cancer genome mutational landscape and proposed rational drug targeting approaches of oncogenic STAT pathway addiction. Hyper-activated STATs and their variants are associated with multiple diseases and are considered high value oncology targets. A full understanding of the molecular basis of member-specific STAT-mediated signaling and the strategies to selectively target them requires examination of the difference in their structures and sequences. • Hyper-activated STATs are a high value oncology pharmacologic target. • Domain-specific variations dictate STAT member-specific activities. • STAT structural data illuminates mechanism of disease-linked STAT mutations. • Member-specific STAT activity is guided by post-translational modifications. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
37. The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells.
- Author
-
Weber, Axel, Borghouts, Corina, Brendel, Christian, Moriggl, Richard, Delis, Natalia, Brill, Boris, Vafaizadeh, Vida, and Groner, Bernd
- Subjects
- *
CYTOKINES , *CELL lines , *APTAMERS , *DNA-binding proteins , *BREAST cancer - Abstract
The signal transducer and activator of transcription Stat5 is transiently activated by growth factor and cytokine signals in normal cells, but its persistent activation has been observed in a wide range of human tumors. Aberrant Stat5 activity was initially observed in leukemias, but subsequently also found in carcinomas. We investigated the importance of Stat5 in human tumor cell lines. shRNA mediated downregulation of Stat5 revealed the dependence of prostate and breast cancer cells on the expression of this transcription factor. We extended these inhibition studies and derived a peptide aptamer (PA) ligand, which directly interacts with the DNA-binding domain of Stat5 in a yeast-two-hybrid screen. The Stat5 specific PA sequence is embedded in a thioredoxin (hTRX) scaffold protein. The resulting recombinant protein S5-DBD-PA was expressed in bacteria, purified and introduced into tumor cells by protein transduction. Alternatively, S5-DBD-PA was expressed in the tumor cells after infection with a S5-DBD-PA encoding gene transfer vector. Both strategies impaired the DNA-binding ability of Stat5, suppressed Stat5 dependent transactivation and caused its intracellular degradation. Our experiments describe a peptide based inhibitor of Stat5 protein activity which can serve as a lead for the development of a clinically useful compound for cancer treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
38. The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma.
- Author
-
Schönefeldt, Susann, Wais, Tamara, Herling, Marco, Mustjoki, Satu, Bekiaris, Vasileios, Moriggl, Richard, and Neubauer, Heidi A.
- Subjects
- *
NEOPLASTIC cell transformation , *MOLECULAR pathology , *IMMUNITY , *HEMATOLOGIC malignancies , *LYMPHOCYTIC leukemia , *GENOMICS , *T cells , *TUMORS , *T-cell lymphoma , *IMMUNOTHERAPY , *SYMPTOMS - Abstract
Simple Summary: γδ T cells play important roles in cancer immunity. Their rapid activation and cytotoxic nature make them promising candidates for use in cell-based immunotherapies; however, under certain conditions, they can induce pro-tumour functions. Furthermore, upon transformation, γδ T cells can develop into aggressive lymphomas with a poor prognosis and no curative therapeutic options. Here, we provide a comprehensive summary of our current knowledge on the complex roles of γδ T cells in cancer. We discuss their anti- and pro-tumour functions in both solid and blood cancers, highlighting the key subsets involved and their potential utility in anti-cancer immunotherapy. We also discuss the mechanisms of γδ T-cell transformation, summarising the resulting γδ T-cell leukaemia/lymphoma entities and their genetic and molecular profiles, as well as current and future treatment strategies. γδ T cells are unique players in shaping immune responses, lying at the intersection between innate and adaptive immunity. Unlike conventional αβ T cells, γδ T cells largely populate non-lymphoid peripheral tissues, demonstrating tissue specificity, and they respond to ligands in an MHC-independent manner. γδ T cells display rapid activation and effector functions, with a capacity for cytotoxic anti-tumour responses and production of inflammatory cytokines such as IFN-γ or IL-17. Their rapid cytotoxic nature makes them attractive cells for use in anti-cancer immunotherapies. However, upon transformation, γδ T cells can give rise to highly aggressive lymphomas. These rare malignancies often display poor patient survival, and no curative therapies exist. In this review, we discuss the diverse roles of γδ T cells in immune surveillance and response, with a particular focus on cancer immunity. We summarise the intriguing dichotomy between pro- and anti-tumour functions of γδ T cells in solid and haematological cancers, highlighting the key subsets involved. Finally, we discuss potential drivers of γδ T-cell transformation, summarising the main γδ T-cell lymphoma/leukaemia entities, their clinical features, recent advances in mapping their molecular and genomic landscapes, current treatment strategies and potential future targeting options. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
39. Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3 -ITD + Acute Myeloid Leukemia.
- Author
-
Bregante, Javier, Schönbichler, Anna, Pölöske, Daniel, Degenfeld-Schonburg, Lina, Monzó Contreras, Garazi, Hadzijusufovic, Emir, de Araujo, Elvin D., Valent, Peter, Moriggl, Richard, and Orlova, Anna
- Subjects
- *
SMALL molecules , *GENETIC mutation , *CLINICAL drug trials , *ACUTE myeloid leukemia , *DRUG resistance , *PROTEIN-tyrosine kinase inhibitors , *DRUG development , *CELL lines - Abstract
Simple Summary: FLT3-ITD mutations belong to the most frequent yet most detrimental genetic alterations in AML. Next-generation FLT3 inhibitors are potent therapeutics and often effective in AML patients carrying the FLT3-ITD driver kinase. However, AML cells are particularly quick in acquiring resistance to FLT3 kinase blockers. We aimed to identify novel therapeutic options for FLT3-ITD+ AML, to investigate possible emerging resistance mechanisms to FLT3 inhibitors and to explore alternative targeting strategies. We applied a kinase-focused drug screen to find alternative therapeutics. We identified ispinesib, a kinesin spindle blocker, and kinase blockers WS6, ponatinib and cabozantinib, as very efficacious agents against FLT3-ITD+ AML cells. Importantly, we identify the combination of cabozantinib and ispinesib as particularly potent against FLT3-ITD+ AML. We suggest that a combinatorial treatment with these drugs could overcome resistance mechanisms and kill FLT3-ITD+ AML blasts. Constitutive activation of FLT3 by ITD mutations is one of the most common genetic aberrations in AML, present in ~1/3 of cases. Patients harboring FLT3-ITD display worse clinical outcomes. The integration and advancement of FLT3 TKI in AML treatment provided significant therapeutic improvement. However, due to the emergence of resistance mechanisms, FLT3-ITD+ AML remains a clinical challenge. We performed an unbiased drug screen to identify 18 compounds as particularly efficacious against FLT3-ITD+ AML. Among these, we characterized two investigational compounds, WS6 and ispinesib, and two approved drugs, ponatinib and cabozantinib, in depth. We found that WS6, although not yet investigated in oncology, shows a similar mechanism and potency as ponatinib and cabozantinib. Interestingly, ispinesib and cabozantinib prevent activation of AXL, a key driver and mechanism of drug resistance in FLT3-ITD+ AML patients. We further investigated synergies between the selected compounds and found that combination treatment with ispinesib and cabozantinib or ponatinib shows high synergy in FLT3-ITD+ AML cell lines and patient samples. Together, we suggest WS6, ispinesib, ponatinib and cabozantinib as novel options for targeting FLT3-ITD+ AML. Whether combinatorial tyrosine kinase and kinesin spindle blockade is effective in eradicating neoplastic (stem) cells in FLT3-ITD+ AML remains to be determined in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
40. Proteomic Analysis Identifies NDUFS1 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer.
- Author
-
Wiebringhaus, Robert, Pecoraro, Matteo, Neubauer, Heidi A., Trachtová, Karolína, Trimmel, Bettina, Wieselberg, Maritta, Pencik, Jan, Egger, Gerda, Krall, Christoph, Moriggl, Richard, Mann, Matthias, Hantusch, Brigitte, and Kenner, Lukas
- Subjects
- *
TISSUE arrays , *ACQUISITION of data methodology , *IMMUNOHISTOCHEMISTRY , *CANCER relapse , *RETROSPECTIVE studies , *PROTEOMICS , *RISK assessment , *CANCER patients , *GENE expression , *GENE expression profiling , *MESSENGER RNA , *MEDICAL records , *TUMOR markers , *PROSTATE tumors , *LONGITUDINAL method , *PHOSPHORYLATION , *DISEASE risk factors - Abstract
Simple Summary: Due to the heterogeneity of prostate cancer (PCa), it is still difficult to provide risk stratification. Metabolic changes in PCa tissue have been described during tumor progression at genetic and transcriptomic level, but these have not yet clearly contributed to improved diagnosis and therapy. The aim of our study was to identify novel markers for aggressive prostate cancer in a proteomics-derived dataset by immunohistochemical analysis and correlation with transcriptomic data. Here, we provide potential new markers—NDUFS1 and ATP5O—for risk stratification in PCa. Additionally, we reveal for the first time a concordant increase of NDUFS1/ATP5O of mRNA expression in transcriptomic datasets and at protein level. We aimed to identify novel markers for aggressive prostate cancer in a STAT3-low proteomics-derived dataset of mitochondrial proteins by immunohistochemical analysis and correlation with transcriptomic data and biochemical recurrence in a STAT3 independent PCa cohort. Formalin-fixed paraffin-embedded tissue (FFPE) sample selection for proteomic analysis and tissue-microarray (TMA) generation was conducted from a cohort of PCa patients. Retrospective data analysis was performed with the same cohort. 153 proteins differentially expressed between STAT3-low and STAT3-high samples were identified. Out of these, 46 proteins were associated with mitochondrial processes including oxidative phosphorylation (OXPHOS), and 45 proteins were upregulated, including NDUFS1/ATP5O. In a STAT3 independent PCa cohort, high expression of NDUFS1/ATP5O was confirmed by immunocytochemistry (IHC) and was significantly associated with earlier biochemical recurrence (BCR). mRNA expression levels for these two genes were significantly higher in intra-epithelial neoplasia and in PCa compared to benign prostate glands. NDUFS1/ATP5O levels are increased both at the mRNA and protein level in aggressive PCa. Our results provide evidence that NDUFS1/ATP5O could be used to identify high-risk PCa patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
41. A Recurrent STAT5B N642H Driver Mutation in Feline Alimentary T Cell Lymphoma.
- Author
-
Kieslinger, Matthias, Swoboda, Alexander, Kramer, Nina, Freund, Patricia, Pratscher, Barbara, Neubauer, Heidi A., Steinborn, Ralf, Wolfesberger, Birgitt, Fuchs-Baumgartinger, Andrea, Moriggl, Richard, and Burgener, Iwan A.
- Subjects
- *
GENETIC mutation , *ANIMAL experimentation , *CATS , *DESCRIPTIVE statistics , *T cells , *T-cell lymphoma , *CARRIER proteins , *RARE diseases - Abstract
Simple Summary: Human gastrointestinal lymphomas are rare diseases with an incidence of one per 1,000,000 inhabitants per year. This paucity poses a major challenge in unravelling their underlying mechanism. In comparison, lymphoma is the most common malignancy in domestic cats and the gastrointestinal (GI) tract is the most common location for this disease. Here, we identify the driver mutation STAT5BN642H in feline alimentary lymphoma, thereby establishing felines as a potential new model for a rare and incurable human T cell disease. Alimentary lymphomas arising from T cells are rare and aggressive malignancies in humans. In comparison, they represent the most common anatomical form of lymphoma in cats. Due to the low prevalence in humans, the underlying pathomechanism for these diseases is poorly characterised, limiting experimental analysis and therapeutic exploration. To date, activating mutations of the JAK/STAT core cancer pathway and particularly the STAT5B oncoprotein have been identified in human enteropathy-associated T cell lymphoma. Here, we describe a high homology of human and feline STAT3 and STAT5B proteins and strong conservation at the genomic level. Analysis of 42 samples of feline T cell alimentary lymphoma reveals broad activation of STAT3 and STAT5B. Screening for known activating mutations in STAT3 or STAT5B identifies the presence of the STAT5BN642H driver mutation in feline enteropathy-associated T cell lymphoma in 7 out of 42 (16.67%) samples in total. Regarding lymphoma subtypes, the majority of mutations with 5 out of 17 (29.41%) cases were found in feline enteropathy-associated lymphoma type II (EATL II). This identification of an oncogenic STAT5B driver mutation in felines recapitulates the genetic situation in the corresponding human disease, thereby establishing the cat as a potential new model for a rare and incurable human T cell disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
42. Ischemic brain injury: A consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction
- Author
-
McGuckin, Colin P., Jurga, Marcin, Miller, Anne-Marie, Sarnowska, Anna, Wiedner, Marc, Boyle, Noreen T., Lynch, Marina A., Jablonska, Anna, Drela, Katarzyna, Lukomska, Barbara, Domanska-Janik, Krystyna, Kenner, Lukas, Moriggl, Richard, Degoul, Olivier, Perruisseau-Carrier, Claire, and Forraz, Nico
- Subjects
- *
ISCHEMIA , *BRAIN injuries , *CONSORTIA , *MESENCHYMAL stem cells , *DISEASE prevalence , *IMMUNOREGULATION - Abstract
Abstract: Increasing global birth rate, coupled with the aging population surviving into their eighth decade has lead to increased incidence diseases, hitherto designated as rare. Brain related ischemia, at birth, or later in life, during, for example stroke, is increasing in global prevalence. Reactive microglia can contribute to neuronal damage as well as compromising transplantion. One potential treatment strategy is cellular therapy, using mesenchymal stem cells (hMSCs), which possess immunomodulatory and cell repair properties. For effective clinical therapy, mechanisms of action must be understood better. Here multicentre international laboratories assessed this question together investigating application of hMSCs neural involvement, with interest in the role of reactive microglia. Modulation by hMSCs in our in vivo and in vitro study shows they decrease markers of microglial activation (lower ED1 and Iba) and astrogliosis (lower GFAP) following transplantation in an ouabain-induced brain ischemia rat model and in organotypic hippocampal cultures. The anti-inflammatory effect in vitro was demonstrated to be CD200 ligand dependent with ligand expression shown to be increased by IL-4 stimulation. hMSC transplant reduced rat microglial STAT3 gene expression and reduced activation of Y705 phosphorylated STAT3, but STAT3 in the hMSCs themselves was elevated upon grafting. Surprisingly, activity was dependent on heterodimerisation with STAT1 activated by IL-4 and Oncostatin M. Our study paves the way to preclinical stages of a clinical trial with hMSC, and suggests a non-canonical JAK-STAT signaling of unphosphorylated STAT3 in immunomodulatory effects of hMSCs. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
43. Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development
- Author
-
Mueller, Kristina M., Themanns, Madeleine, Friedbichler, Katrin, Kornfeld, Jan-Wilhelm, Esterbauer, Harald, Tuckermann, Jan P., and Moriggl, Richard
- Subjects
- *
GLUCOCORTICOID receptors , *SOMATOTROPIN , *CELLULAR signal transduction , *LIVER cancer , *FATTY degeneration , *HOMEOSTASIS , *METABOLIC disorders - Abstract
Abstract: Growth hormone (GH) and glucocorticoids (GCs) are involved in the control of processes that are essential for the maintenance of vital body functions including energy supply and growth control. GH and GCs have been well characterized to regulate systemic energy homeostasis, particular during certain conditions of physical stress. However, dysfunctional signaling in both pathways is linked to various metabolic disorders associated with aberrant carbohydrate and lipid metabolism. In liver, GH-dependent activation of the transcription factor signal transducer and activator of transcription (STAT) 5 controls a variety of physiologic functions within hepatocytes. Similarly, GCs, through activation of the glucocorticoid receptor (GR), influence many important liver functions such as gluconeogenesis. Studies in hepatic Stat5 or GR knockout mice have revealed that they similarly control liver function on their target gene level and indeed, the GR functions often as a cofactor of STAT5 for GH-induced genes. Gene sets, which require physical STAT5–GR interaction, include those controlling body growth and maturation. More recently, it has become evident that impairment of GH-STAT5 signaling in different experimental models correlates with metabolic liver disease, ranging from hepatic steatosis to hepatocellular carcinoma (HCC). While GH-activated STAT5 has a protective role in chronic liver disease, experimental disruption of GC-GR signaling rather seems to ameliorate metabolic disorders under metabolic challenge. In this review, we focus on the current knowledge about hepatic GH-STAT5 and GC-GR signaling in body growth, metabolism, and protection from fatty liver disease and HCC development. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
44. A mouse model to identify cooperating signaling pathways in cancer.
- Author
-
Musteanu, Monica, Blaas, Leander, Zenz, Rainer, Svinka, Jasmin, Hoffmann, Thomas, Grabner, Beatrice, Schramek, Daniel, Kantner, Hans-Peter, Müller, Mathias, Kolbe, Thomas, Rülicke, Thomas, Moriggl, Richard, Kenner, Lukas, Stoiber, Dagmar, Penninger, Josef Martin, Popper, Helmut, Casanova, Emilio, and Eferl, Robert
- Subjects
- *
CELLULAR signal transduction , *ONCOGENES , *TUMOR growth , *GENE expression , *TISSUES , *CARCINOGENESIS , *LABORATORY mice - Abstract
We here establish a mouse cancer model called Multi-Hit that allows for the evaluation of oncogene cooperativities in tumor development. The model is based on the stochastic expression of oncogene combinations ('hits') that are mediated by Cre in a given tissue. Cells with cooperating hits are positively selected and give rise to tumors. We used this approach to evaluate the requirement of Ras downstream effector pathways in tumorigenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
45. STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter.
- Author
-
Zugowski, Constance, Lieder, Franziska, Müller, Annekatrin, Gasch, Josephine, Corvinus, Florian M., Moriggl, Richard, and Friedrich, Karlheinz
- Subjects
- *
METALLOPROTEINASES , *GENE expression , *COLON cancer , *CANCER cells , *TRANSCRIPTION factors , *PROMOTERS (Genetics) , *BINDING sites - Abstract
Aberrant activation of STAT3 in colorectal carcinoma (CRC) tissue is correlated with elevated expression of matrix metalloproteinase-1 (MMP-1). We analyzed transcriptional regulation of the human MMP-1 promoter in CRC cells by tyrosine phosphorylated (pY-) STAT3. One of six putative STAT binding elements within a 4.3 kb MMP-1 trancriptional promoter fragment showed a particular high affinity for STAT3 in vitro. However, the most profound regulatory influence on MMP-1 promoter activity resides in a proximal region relative to the transcriptional start, bearing a pair of putative binding sites for STAT3 and AP-1. Mutational analysis of the combined STAT3/AP-1 recognition element revealed that the integrity of the STAT3 binding site is necessary, but not sufficient for both DNA interaction and transcriptional regulation by activated STAT3. Instead, the adjacent AP-1 site was essential for pY-STAT3-mediated transcription on the MMP-1 promoter. DNA-protein binding assays provided strong evidence for complex formation of STAT3 and c-Jun governed by protein-protein contacts. We observed striking coincidence for concerted aberrant activation of both STAT3 and AP-1 in human colon cancer specimens. This finding supports the notion that the combination of inappropriate STAT3 and AP-1 activities drives elevated MMP-1 expression and tissue invasion in colorectal cancer and is of clinical relevance. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
46. Promising New Sources for Pluripotent Stem Cells.
- Author
-
Leeb, Christian, Jurga, Marcin, McGuckin, Colin, Moriggl, Richard, and Kenner, Lukas
- Subjects
- *
STEM cell research , *EMBRYONIC stem cell research , *NEUROPLASTICITY , *REGENERATIVE medicine , *PLASTIC embedding , *HUMAN embryos - Abstract
Recent findings have placed stem cell research at the forefront of biomedical sciences. Basic research on embryonic stem cells (ESCs) has contributed to our knowledge about the developmental potential and plasticity of stem cells. Furthermore, it has raised hope to use these cells as potential source for regenerative medicine and tissue replacement after injury or disease. Unfortunately, ESCs can also form tumors and they are ethically controversial because they originate from human embryos. This review summarizes findings and therapeutic applications of ESCs and their alternatives: adult stem cells and iPS cells. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
47. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling.
- Author
-
Pflegerl, Pamina, Vesely, Paul, Hantusch, Brigitte, Schiederer, Michaela, Zenz, Rainer, Janig, Elke, Steiner, Günter, Meixner, Arabella, Petzelbauer, Peter, WoIf, Peter, Soleiman, Afschin, Egger, Gerda, Moriggl, Richard, Kishimoto, Tadamitsu, Wagner, Erwin F., and Kenner, Lukas
- Subjects
- *
SYSTEMIC lupus erythematosus , *T cells , *B cells , *CYTOKINES , *MYELOPROLIFERATIVE neoplasms , *KERATINOCYTES - Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various tissues. Involvement of B and T cells as well as increased cytokine levels have been associated with disease manifestation. Recently, we demonstrated that mice with epider- mal loss of JunB (JunBΔeP) develop a myeloproliferative syndrome (MPS) due to high levels of G-CSF which are secreted by JunB-deficient keratinocytes. In addition, we show that JunBΔeP mice develop a SLE phenotype linked to increased epidermal interleukin 6 (IL-6) secretion. lntercrosses with IL-6-deficient mice could rescue the SLE phenotype. Furthermore, we show that JunB binds to the IL-6 promoter and transcriptionally suppresses IL-6. Facial skin biopsies of human SLE patients similarly revealed low JunB protein expression and high IL-6, activated Stat3, Socs-1, and Socs-3 levels within lupus lesions. Thus, keratinocyte-induced IL-6 secretion can cause SLE and systemic autoimmunity. Our results support trials to use α-IL-6 receptor antibody therapy for treatment of SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
48. Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition.
- Author
-
Pons, Miriam, Zeyn, Yanira, Zahn, Stella, Mahendrarajah, Nisintha, Page, Brent D. G., Gunning, Patrick T., Moriggl, Richard, Brenner, Walburgis, Butter, Falk, and Krämer, Oliver H.
- Subjects
- *
BIOLOGICAL models , *HYDROXYUREA , *CHRONIC myeloid leukemia , *THREONINE , *APOPTOSIS , *ACUTE myeloid leukemia , *ANTINEOPLASTIC agents , *PROTEOMICS , *PROTEIN-tyrosine kinases , *SERINE , *PHARMACODYNAMICS - Abstract
Simple Summary: Leukemic cells show differential sensitivity to apoptosis induction by the clinically relevant drug hydroxyurea. Since resistance to hydroxyurea can pose a therapeutic problem, we searched for mechanisms that protect such cells from the toxic effects of hydroxyurea. We used proteomics followed by mass spectrometry to accomplish this task and noted a loss of the RAF1 kinase in cells that are killed by hydroxyurea. Pharmacological inhibition of RAF1 and its target BCL-XL show that these proteins suppress apoptosis induction. Furthermore, inhibition of their upstream regulators BCR-ABL1 (in chronic myeloid leukemia cells) and FLT3-ITD (in acute myeloid leukemia cells) plus hydroxyurea produced favorable results. This approach may benefit patients that are not successfully treated with tyrosine kinase inhibitors. Taken together, we provide novel insights into strategies that eliminate chronic and acute myeloid leukemia cells with combinations of clinically established and currently tested pharmaceutical agents. The ribonucleotide reductase inhibitor hydroxyurea suppresses de novo dNTP synthesis and attenuates the hyperproliferation of leukemic blasts. Mechanisms that determine whether cells undergo apoptosis in response to hydroxyurea are ill-defined. We used unbiased proteomics to uncover which pathways control the transition of the hydroxyurea-induced replication stress into an apoptotic program in chronic and acute myeloid leukemia cells. We noted a decrease in the serine/threonine kinase RAF1/c-RAF in cells that undergo apoptosis in response to clinically relevant doses of hydroxyurea. Using the RAF inhibitor LY3009120, we show that RAF activity determines the sensitivity of leukemic cells toward hydroxyurea. We further disclose that pharmacological inhibition of the RAF downstream target BCL-XL with the drug navitoclax and RNAi combine favorably with hydroxyurea against leukemic cells. BCR-ABL1 and hyperactive FLT3 are tyrosine kinases that causally contribute to the development of leukemia and induce RAF1 and BCL-XL. Accordingly, the ABL inhibitor imatinib and the FLT3 inhibitor quizartinib sensitize leukemic cells to pro-apoptotic effects of hydroxyurea. Moreover, hydroxyurea and navitoclax kill leukemic cells with mutant FLT3 that are resistant to quizartinib. These data reveal cellular susceptibility factors toward hydroxyurea and how they can be exploited to eliminate difficult-to-treat leukemic cells with clinically relevant drug combinations. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
49. STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output
- Author
-
Li, Geqiang, Wang, Zhengqi, Zhang, Yi, Kang, Zizhen, Haviernikova, Eleonora, Cui, Yongzhi, Hennighausen, Lothar, Moriggl, Richard, Wang, Demin, Tse, William, and Bunting, Kevin D.
- Subjects
- *
BLOOD cells , *BONE marrow cells , *HEMATOPOIETIC stem cells , *BILIARY tract - Abstract
Objective: Signal transducer and activator of transcription 5 (STAT5) is a critical regulator of hematopoietic development and its impaired activation is associated with hematopoietic and immune cell defects. However, much of this information has been learned from knockout mice that still retain the potential for expression of STAT5 proteins that are N-terminally truncated due to alternative internal translation initiation codons. The goal of these studies was to use transplantation-based assays to analyze the degree of STAT5ΔN activity in hematopoietic stem cells (HSC) and throughout lymphomyeloid development. Methods: We have directly compared E14.5 fetal liver cells from mice with potential to express STAT5abΔN (STAT5abΔN/ΔN) with mice completely lacking STAT5a and STAT5b (STAT5abnull/null). We have also utilized retroviral complementation of STAT5abnull/null fetal liver HSC to enforce expression of full-length STAT5a or STAT5a lacking the first 136 amino acids (STAT5aΔN). Results: We report that STAT5 is required for HSC, lymphocyte, and erythrocyte development. We demonstrate that restored expression of STAT5a in STAT5abnull/null HSC provides a strong selective advantage, correcting T- and B-lymphocyte and erythrocyte development. Interestingly, Gr-1+ blood cells were inversely correlated with B lymphocytes and both were normalized by STAT5a expression. In contrast, transduction of STAT5aΔN only provided partial B-lymphocyte development. Conclusions: These studies define the role of STAT5 in maintaining normal lymphoid vs myeloid balance during hematopoiesis and highlight a major role for the N-domain in HSC function. The platform of retroviral complementation described here will be particularly useful for future studies to subdefine the N-domain regions that are critical for hematopoiesis. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
50. Apoptosis Protection by the Epo Target Bcl-XL Allows Factor-Independent Differentiation of Primary Erythroblasts
- Author
-
Dolznig, Helmut, Habermann, Bianca, Stangl, Katharina, Deiner, Eva Maria, Moriggl, Richard, Beug, Hartmut, and Müllner, Ernst W.
- Subjects
- *
ERYTHROPOIETIN , *GENE targeting ,APOPTOSIS prevention - Abstract
Background: Erythropoietin (Epo) is required for correct execution of the erythroid differentiation program. Erythropoiesis requires Bcl-XL , a major late target of Epo-receptor signaling. Mice lacking Bcl-XL die around embryonic age E12.5, forming normal erythroid progenitors but lacking functional red cells. Recently, serum-free culture conditions for expansion of murine red cell progenitors were developed, yielding cells capable of in vivo-like terminal differentiation into enucleated erythrocytes, in response to Epo/insulin. Here we address whether Epo function during terminal maturation involves a cytokine-independent “default program,” requiring only apoptosis inhibition through Epo-dependent upregulation of Bcl-XL.Results: Exogenous expression of Bcl-XL or Bcl-2 in primary murine erythroblasts or clonal erythroblast lines derived from p53−/− mice allowed these cells to undergo terminal erythroid maturation, in the complete absence of cytokines. A potential autocrine Epo loop was ruled out by respective neutralizing antibodies. Importantly, sustained proliferation of Bcl-XL-expressing immature erythroblasts still required respective factors (Epo, stem cell factor [SCF], and the glucocorticoid receptor ligand dexamethasone [Dex]). Epo-independent differentiation in these Bcl-XL- or Bcl-2-expressing, primary erythroblasts was thus triggered by removal of the renewal factors SCF and Dex. This initiated the maturation-specific expression cascade of erythroid transcription factors, followed by differentiation divisions (characterized by a short G1 phase and decrease in cell size), hemoglobin accumulation, and enucleation.Conclusions: During erythroid maturation, Epo regulates red cell numbers via apoptosis inhibition, caused by Epo-dependent upregulation of the antiapoptotic protein Bcl-XL. This allows “default” terminal differentiation of apoptosis-protected, committed erythroblasts, independent of any exogenous signals. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.